Reviewing the unsubstantiated claims for the methodological superiority of 'placebo' over 'active' controlled trials: Reply to open peer commentaries

American Journal of Bioethics

Volumn 9, Issue 9, 2009, Pages

  Howick, Jeremy ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ARTICLE; CONTROLLED CLINICAL TRIAL; DOCTOR PATIENT RELATION; ETHICS; HUMAN; HUMAN RELATION; MEDICAL ETHICS; METHODOLOGY; MORALITY; NEUROLOGIC DISEASE; PLACEBO EFFECT; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; RESEARCH SUBJECT; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

CONTROLLED CLINICAL TRIALS AS TOPIC; ETHICS, CLINICAL; ETHICS, MEDICAL; ETHICS, RESEARCH; HUMANS; MORAL OBLIGATIONS; NERVOUS SYSTEM DISEASES; PHYSICIAN-PATIENT RELATIONS; PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUBJECTS; RESEARCHER-SUBJECT RELATIONS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

EID: 70449572808     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160903149417     Document Type: Article

References (24)

1. The EC/IC bypass study group. 1985. Failure of extracranial intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC bypass study group. New England Journal of Medicine 313(19): 1191-200.
2. Anderson, J. A. 2006. The ethics and science of placebo-controlled trials: Assay sensitivity and the duhem-quine thesis. Journal of Medicine and Philosophy 31: 65-81.
3. Anderson, J. A. 2009. Who's in control of the choice of control. American Journal of Bioethics-Neuroscience 9(9): 60-62.
4. Benedetti, F., and Amanzio, M. 1997. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Progressive Neurobiology 52(2): 109-125.
5. Bhardwaj, S. S., Camacho, F., Derrow, A., Fleischer, Jr., A. B., and Feldman, S. R. 2004. Statistical significance and clinical relevance: The importance of power in clinical trials in dermatology. Archives of Dermatology 140(12): 1520-1523.
6. Dworkin, R. 2009. A clinical perspective on placebo research: Looking back, looking forward.American Journal of Bioethics-Neuroscience 9(9): 54-55.
7. Enkin, M. 2009. Questioning the methodological superiority of 'placebo' over 'active' controlledtrials. American Journal ofBioethics-Neuroscience 9(9): 66-67.
8. Golomb, B. 2009. Control theory: placebo-controlled drug trials have problems. Active-controlled drug trials are not always the solution. American Journal of Bioethics-Neuroscience 9(9): 67-69.
9. Golomb, B. A. 1995. Paradox of placebo effect. Nature 375(6532): 530.
10. Horng, S. H., and Miller, F. G. 2007. Placebo-controlled procedural trials for neurological conditions. Neurotherapeutics 4(3): 531-536.
11. Howick, J. (2009). Examining the alleged methodological superiority of placebo over 'active' controls. American Journal of Bioethics-Neuroscience 9(9): 34-48.
12. ICH 2002. ICH (International Conference on Harmonization) Harmonized Tripartite Guideline. Guideline for Good Clinical Practice. E6.
13. Miller, F. 2009. The rationale for placebo-controlled trials: Methodology and policy considerations. American Journal of Bioethics-Neuroscience 9(9): 49-50.
14. Moerman, D. E. (2000). Cultural variations in the placebo effect: Ulcers, anxiety, and blood pressure. Medical Anthropology Quarterly 14(1): 51-72.
15. Moerman, D.E. 2009. Research, medicine, and "placebos". American Journal of Bioethics-Neuroscience 9(9): 64-65.
16. Morgan, S. G., Bassett, K. L., Wright, J. M., Evans, R. G., Barer, M. L., Caetano, P. A. et al. 2005. "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada.BritishMedicalJournal 331(7520): 815-816.
17. Nunn, R. 2009a. It's time to put the placebo out of its misery. British Medical Journal 338: 1015.
18. Nunn, R. 2009b. Preparing for a post-placebo paradigm. American Journal of Bioethics-Neuroscience 9(9): 51-52.
19. Petrini, C. 2009. Ethical issues in the difference betweend placebocontrolled and active-controlled trials. American Journal of Bioethics-Neuroscience 9(9): 56-58.
20. Rennie, S., and Strümer, T. 2009. Strengthening Howick's argument against the alleged superiority of placebo-controlled trials. American Journal of Bioethics-Neuroscience 9(9): 62-64.
21. Sackett, D. L., Spitzer, W. O., Gent, M. and Roberts, R. S. 1974. The Burlington randomized trial of the nurse practitioner: Health outcomes of patients. Annals of Internal Medicine 80(2): 137-142.
22. Senn, S. 2009. Placebo misconceptions. American Journal of BioethicsNeuroscience 9(9): 53-54.
23. van der Graaf, R. 2009. Conflating scientific with clinical considerations. American Journal of Bioethics-Neuroscience 9(9): 58-59.
24. WMA 2001. Note of Clarification on Paragraph 29 of the WMA Declaration of Helsinki, Geneva. W. M. Association, World Medical Association.